See more : Titan Petrochemicals Group Limited (1192.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Haemonetics Corporation (HAE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haemonetics Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Varta AG (VARGF) Income Statement Analysis – Financial Results
- Ever Fortune.AI Co., Ltd. (6841.TWO) Income Statement Analysis – Financial Results
- BankInvest Højt Udbytte Aktier Akk. KL (BAIHU.CO) Income Statement Analysis – Financial Results
- Medaro Mining Corp. (MEDA.CN) Income Statement Analysis – Financial Results
- Public Joint Stock Company Kamchatskenergo (KCHE.ME) Income Statement Analysis – Financial Results
Haemonetics Corporation (HAE)
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31B | 1.17B | 993.20M | 870.46M | 988.48M | 967.58M | 903.92M | 886.12M | 909.68M | 910.37M | 938.51M | 891.99M | 727.84M | 676.69M | 645.43M | 597.88M | 516.44M | 449.61M | 419.73M | 383.60M | 364.23M | 336.96M | 319.97M | 293.86M | 277.92M | 282.10M | 285.80M | 309.80M | 278.20M | 262.40M | 248.40M | 216.30M | 176.40M | 157.30M |
| Cost of Revenue | 617.51M | 553.56M | 487.69M | 472.63M | 503.97M | 550.04M | 492.02M | 507.62M | 503.80M | 475.96M | 470.14M | 463.86M | 358.60M | 321.49M | 307.95M | 289.71M | 258.72M | 222.31M | 199.20M | 185.72M | 192.11M | 182.26M | 165.14M | 126.95M | 121.70M | 124.00M | 127.10M | 137.80M | 110.50M | 103.90M | 94.20M | 88.80M | 78.50M | 0.00 |
| Gross Profit | 691.55M | 615.10M | 505.50M | 397.84M | 484.51M | 417.54M | 411.91M | 378.49M | 405.87M | 434.42M | 468.37M | 428.13M | 369.24M | 355.21M | 337.48M | 308.17M | 257.73M | 227.30M | 220.54M | 197.88M | 172.12M | 154.70M | 154.83M | 166.91M | 156.22M | 158.10M | 158.70M | 172.00M | 167.70M | 158.50M | 154.20M | 127.50M | 97.90M | 157.30M |
| Gross Profit Ratio | 52.83% | 52.63% | 50.90% | 45.70% | 49.02% | 43.15% | 45.57% | 42.71% | 44.62% | 47.72% | 49.91% | 48.00% | 50.73% | 52.49% | 52.29% | 51.54% | 49.90% | 50.56% | 52.54% | 51.58% | 47.26% | 45.91% | 48.39% | 56.80% | 56.21% | 56.04% | 55.53% | 55.52% | 60.28% | 60.40% | 62.08% | 58.95% | 55.50% | 100.00% |
| Research & Development | 54.44M | 50.13M | 46.80M | 32.86M | 30.88M | 35.71M | 39.23M | 37.56M | 45.57M | 54.19M | 54.20M | 48.64M | 36.80M | 32.66M | 26.38M | 23.86M | 24.32M | 23.88M | 26.52M | 19.99M | 17.79M | 19.51M | 19.51M | 19.04M | 14.93M | 15.10M | 17.90M | 19.00M | 18.50M | 16.70M | 15.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 424.68M | 369.48M | 335.16M | 271.49M | 295.38M | 293.78M | 313.42M | 299.23M | 320.07M | 335.19M | 363.24M | 314.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.10M | 7.20M | 4.40M | 2.70M | 4.30M | 4.50M | 3.10M | 2.50M | 3.90M | 4.50M | 3.60M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 431.78M | 376.68M | 339.56M | 274.19M | 299.68M | 298.28M | 316.52M | 301.73M | 323.97M | 339.69M | 366.84M | 318.81M | 245.26M | 213.90M | 214.48M | 198.74M | 163.12M | 137.07M | 121.35M | 118.04M | 108.45M | 97.71M | 88.87M | 86.73M | 82.76M | 86.70M | 86.90M | 92.30M | 81.80M | 75.70M | 75.90M | 77.20M | 61.00M | 0.00 |
| Other Expenses | 40.45M | 32.26M | 47.41M | 32.83M | 50.60M | 0.00 | 0.00 | -8.10M | 87.67M | 5.44M | 1.71M | -6.54M | 0.00 | -1.89M | 13.34M | 0.00 | 0.00 | -5.48M | -26.35M | -100.00K | 0.00 | 0.00 | 0.00 | 4.61M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| Operating Expenses | 526.67M | 459.06M | 433.78M | 339.88M | 330.56M | 333.99M | 355.75M | 339.28M | 369.54M | 393.88M | 421.04M | 367.45M | 282.06M | 244.66M | 240.86M | 222.60M | 187.44M | 155.48M | 121.52M | 137.93M | 126.24M | 117.22M | 108.39M | 110.39M | 122.59M | 126.40M | 127.70M | 123.60M | 113.40M | 106.10M | 102.40M | 85.70M | 68.00M | 0.00 |
| Cost & Expenses | 1.14B | 459.06M | 921.47M | 812.50M | 834.53M | 884.03M | 847.77M | 846.90M | 873.34M | 869.83M | 891.18M | 831.31M | 640.67M | 566.15M | 548.81M | 512.31M | 446.15M | 377.79M | 320.72M | 323.66M | 318.35M | 299.48M | 273.52M | 237.34M | 244.29M | 250.40M | 254.80M | 261.40M | 223.90M | 210.00M | 196.60M | 174.50M | 146.50M | 0.00 |
| Interest Income | 0.00 | 13.00M | 5.80M | 9.40M | 13.50M | 9.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 384.00K | 399.00K | 1.97M | 0.00 | 7.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.02M | 14.63M | 17.12M | 16.83M | 16.20M | 9.91M | 4.53M | 8.10M | 9.47M | 9.38M | 10.93M | 6.54M | 0.00 | 6.00K | 742.00K | 64.00K | 0.00 | 97.00K | 0.00 | 0.00 | 0.00 | 0.00 | 13.58M | 59.39M | 13.10M | 0.00 | 74.90M | 0.00 | 0.00 | 0.00 | 0.00 | 1.60M | 1.60M | 0.00 |
| Depreciation & Amortization | 97.22M | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M | 89.25M | 89.73M | 89.91M | 86.05M | 81.74M | 65.48M | 49.97M | 48.15M | 43.24M | 36.46M | 31.20M | 27.50M | 25.15M | 27.58M | 30.15M | 28.43M | 25.62M | 24.50M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| EBITDA | 265.58M | 249.34M | 178.50M | 142.25M | 264.24M | 192.96M | 153.03M | 70.35M | 45.97M | 125.72M | 127.04M | 124.58M | 139.46M | 158.23M | 125.25M | 121.53M | 101.48M | 101.10M | 124.17M | 87.52M | 77.44M | 65.91M | 72.06M | 81.02M | 73.13M | 51.20M | 53.90M | 72.00M | 67.40M | 66.10M | 62.50M | 50.30M | 36.90M | 157.30M |
| EBITDA Ratio | 20.29% | 21.34% | 17.06% | 16.34% | 26.73% | 19.94% | 16.09% | 14.55% | 13.89% | 4.45% | 5.04% | 6.80% | 11.66% | 23.51% | 15.03% | 20.74% | 19.27% | 22.23% | 22.63% | 22.78% | 20.60% | 18.85% | 25.00% | 34.44% | 23.56% | 18.15% | 26.91% | 18.30% | 23.08% | 24.43% | 24.07% | 23.16% | 20.58% | 100.00% |
| Operating Income | 164.88M | 156.03M | 80.75M | 57.96M | 153.95M | 83.55M | 56.16M | -19.38M | -43.98M | 40.54M | 47.33M | 56.44M | 88.76M | 110.55M | 83.28M | 85.57M | 70.29M | 62.75M | 99.02M | 59.94M | 45.88M | 37.48M | 36.45M | 13.42M | 33.63M | 31.70M | 31.00M | 48.40M | 54.30M | 52.40M | 51.80M | 41.80M | 29.90M | 157.30M |
| Operating Income Ratio | 12.60% | 13.35% | 8.13% | 6.66% | 15.57% | 8.63% | 6.21% | -2.19% | -4.84% | 4.45% | 5.04% | 6.33% | 12.19% | 16.34% | 12.90% | 14.31% | 13.61% | 13.96% | 23.59% | 15.63% | 12.60% | 11.12% | 11.39% | 4.57% | 12.10% | 11.24% | 10.85% | 15.62% | 19.52% | 19.97% | 20.85% | 19.33% | 16.95% | 100.00% |
| Total Other Income/Expenses | -13.02M | -14.63M | -17.12M | 14.95M | -16.20M | -9.91M | 3.48M | -8.10M | -97.14M | -9.38M | -10.93M | -6.54M | 740.00K | -467.00K | -2.01M | -565.00K | 7.02M | 9.59M | 7.86M | -102.00K | -65.00K | 1.13M | 2.06M | 3.91M | 3.25M | 969.00K | -26.50M | 2.30M | 900.00K | 100.00K | -1.00M | -1.80M | -2.20M | -157.30M |
| Income Before Tax | 151.87M | 141.40M | 63.63M | 72.91M | 87.15M | 73.63M | 59.63M | -27.48M | -53.46M | 31.17M | 36.40M | 49.90M | 89.50M | 110.08M | 81.27M | 85.00M | 77.30M | 72.34M | 106.88M | 59.84M | 45.81M | 38.61M | 38.51M | 17.33M | 27.33M | 32.60M | 4.50M | 50.70M | 55.20M | 52.50M | 50.80M | 40.00M | 27.70M | 0.00 |
| Income Before Tax Ratio | 11.60% | 12.10% | 6.41% | 8.38% | 8.82% | 7.61% | 6.60% | -3.10% | -5.88% | 3.42% | 3.88% | 5.59% | 12.30% | 16.27% | 12.59% | 14.22% | 14.97% | 16.09% | 25.46% | 15.60% | 12.58% | 11.46% | 12.03% | 5.90% | 9.83% | 11.56% | 1.57% | 16.37% | 19.84% | 20.01% | 20.45% | 18.49% | 15.70% | 0.00% |
| Income Tax Expense | 34.31M | 26.00M | 20.25M | -6.56M | 10.63M | 18.61M | 14.06M | -1.21M | 2.16M | 14.27M | 1.25M | 11.10M | 22.61M | 30.10M | 22.90M | 25.70M | 25.32M | 23.23M | 37.81M | 20.20M | 16.49M | 10.23M | 10.78M | 10.09M | 8.47M | 11.40M | 3.90M | 17.70M | 19.30M | 18.90M | 19.30M | 15.20M | 9.70M | 0.00 |
| Net Income | 117.56M | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M | 45.57M | -26.27M | -55.62M | 16.90M | 35.15M | 38.80M | 66.89M | 79.98M | 58.38M | 59.30M | 51.98M | 49.11M | 69.08M | 39.64M | 29.32M | 28.38M | 30.03M | 7.24M | 19.00M | 21.10M | -24.80M | 33.00M | 35.90M | 33.60M | 31.50M | 24.80M | 18.00M | 0.00 |
| Net Income Ratio | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | 5.04% | -2.96% | -6.11% | 1.86% | 3.75% | 4.35% | 9.19% | 11.82% | 9.04% | 9.92% | 10.07% | 10.92% | 16.46% | 10.33% | 8.05% | 8.42% | 9.38% | 2.46% | 6.84% | 7.48% | -8.68% | 10.65% | 12.90% | 12.80% | 12.68% | 11.47% | 10.20% | 0.00% |
| EPS | 2.32 | 2.27 | 0.85 | 1.57 | 1.51 | 1.07 | 0.86 | -0.51 | -1.09 | 0.33 | 0.68 | 0.76 | 1.30 | 1.59 | 1.15 | 1.17 | 1.00 | 0.92 | 1.29 | 0.77 | 0.60 | 0.57 | 0.57 | 0.14 | 0.30 | 0.39 | -0.47 | 0.61 | 0.66 | 0.61 | 0.56 | 0.45 | 0.33 | 0.26 |
| EPS Diluted | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 | 1.04 | 0.85 | -0.51 | -1.09 | 0.32 | 0.67 | 0.74 | 1.30 | 1.56 | 1.12 | 1.14 | 0.97 | 0.89 | 1.25 | 0.75 | 0.60 | 0.56 | 0.56 | 0.14 | 0.29 | 0.39 | -0.47 | 0.60 | 0.65 | 0.59 | 0.55 | 0.44 | 0.32 | 0.25 |
| Weighted Avg Shares Out | 50.71M | 50.78M | 51.05M | 50.69M | 50.69M | 51.53M | 52.76M | 51.51M | 50.91M | 51.53M | 51.61M | 51.35M | 50.73M | 50.15M | 50.90M | 50.78M | 51.65M | 53.49M | 52.96M | 51.05M | 48.87M | 49.18M | 52.43M | 50.60M | 52.17M | 53.49M | 52.77M | 54.38M | 54.39M | 55.54M | 55.75M | 55.73M | 55.38M | 55.60M |
| Weighted Avg Shares Out (Dil) | 51.40M | 51.42M | 51.35M | 51.29M | 51.82M | 52.94M | 53.50M | 51.52M | 50.91M | 52.09M | 52.38M | 52.26M | 51.59M | 51.19M | 52.13M | 52.35M | 53.49M | 55.30M | 54.95M | 52.85M | 49.28M | 50.10M | 54.31M | 52.01M | 53.00M | 53.77M | 53.33M | 54.83M | 55.23M | 56.95M | 57.80M | 57.01M | 57.14M | 55.60M |
Are Investors Undervaluing Haemonetics (HAE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 27.8% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025.
4 Medical Product Stocks to Buy From a Prospective Industry
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A
BOSTON , Dec. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its whole...
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Here's Why Haemonetics (HAE) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wall Street Analysts Think Haemonetics (HAE) Could Surge 25.58%: Read This Before Placing a Bet
The mean of analysts' price targets for Haemonetics (HAE) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.
Compared to Estimates, Haemonetics (HAE) Q2 Earnings: A Look at Key Metrics
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Source: https://incomestatements.info
Category: Stock Reports